Gut microbiome alterations in patients with stage 4 hepatitis C by unknown
Aly et al. Gut Pathog  (2016) 8:42 
DOI 10.1186/s13099-016-0124-2
RESEARCH
Gut microbiome alterations in patients 
with stage 4 hepatitis C
AbdelRahman Mahmoud Aly1, AbdelReheem Adel1, Ahmed Osama El‑Gendy2, Tamer M. Essam3 
and Ramy K. Aziz3*
Abstract 
Background: Hepatitis C virus (HCV) causes debilitating liver diseases, which may progress to cirrhosis and cancer, 
and claims 500,000 annual lives worldwide. While HCV epidemiology, pathophysiology, and therapy are being deeply 
studied, rare attention is given to reciprocal interactions between HCV infection , HCV‑induced chronic liver diseases, 
and the human gut microbiome. As Egypt has the world’s highest prevalence of HCV infections, we launched this 
study to monitor differences in the gut microbial community composition of Egyptian HCV patients that may affect, 
or result from, the patients’ liver state.
Results: To this end, we analyzed stool samples from six stage 4‑HCV patients and eight healthy individuals by high‑
throughput 16S rRNA gene sequencing using Illumina MiSeq. Overall, the alpha‑diversity of the healthy persons’ gut 
microbiomes was higher than those of the HCV patients. Whereas members of phylum Bacteroidetes were more 
abundant in HCV patients, healthy individuals had higher abundance of Firmicutes, Proteobacteria, and Actinobacte‑
ria. Genus‑level analysis showed differential abundance of Prevotella and Faecalibacterium (higher in HCV patients) vs. 
Ruminococcus and Clostridium (healthy group), indicating that the higher abundance of Bacteroidetes in HCV patients 
is most likely due to Prevotella overabundance. The probiotic genus, Bifidobacterium, was only observed in the micro‑
biotas of healthy individuals.
Conclusions: To the best of our knowledge, this study provides a first overview of major phyla and genera differenti‑
ating stage 4‑HCV patients from healthy individuals and suggests possible microbiome remodeling in chronic hepa‑
titis C, possibly shaped by bacterial translocation as well as the liver’s impaired role in digestion and protein synthesis. 
Future studies will investigate the microbiome composition and functional capabilities in more patients while tracing 
some potential biomarker taxa (e.g., Prevotella, Faecalibacterium vs. Bifidobacterium).
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sequencing, Next‑generation sequencing
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Background
About 130–150 million people suffer from chronic hepa-
titis C virus (HCV) infection worldwide, and about half 
a million people die every year because of this resilient 
virus [1]. Egypt has the highest prevalence of HCV in the 
world, estimated as 13.9–14.7  % [2, 3]. This means that 
~13 million Egyptians are currently infected by HCV.
This virus infects liver cells leading to dramatic physi-
ological and pathophysiological changes. The human 
liver plays a crucial role in the body’s homeostasis, as 
most blood proteins are produced by the liver cells (e.g., 
serum albumin, α-fetoprotein, soluble plasma fibronec-
tin, coagulation cascade and inhibitors of coagulation 
proteins, and C-reactive protein) [4]. Thus, after HCV 
infection, the virus starts to destroy hepatic cells, nega-
tively impacting the body’s homeostasis and leading 
to other dangerous consequences, e.g., chronic liver 
inflammation, cirrhosis and hepatocellular carcinoma 
(HCC). HCV patients may experience acute or chronic 
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pathological events after infection. About 15–45  % of 
HCV patients may clear the virus within 6  months of 
infection without any treatment; however, 55–85  % will 
develop chronic HCV infection through 20 years, leading 
to cirrhosis and HCC [5].
A major part of ongoing research focuses on the cau-
sality relationship between HCV infection and its sub-
sequent pathophysiological consequences. Surprisingly 
though, little is known about the interplay between HCV 
infection, its complications, and the human gut microbi-
ome [6, 7].
The human body carries 1014 microbial cells, outnum-
bering human cells and contributing about 1.5 kg weight 
[8]. The genetic content of these microbial communities 
is estimated at 100× more than human genes, which 
undoubtedly suggests an important role that the micro-
biota plays in human health and diseases. For example, 
gut microbes play a major role in vitamin synthesis, food 
digestion, and immune system development [9]. Altera-
tions of gut community composition have been linked 
to several diseases, such as rheumatoid arthritis [10], 
colorectal cancer [11], obesity [12], depression, anxiety, 
autism, and others [13]. Furthermore, accruing data sug-
gest a pivotal role for the gut microbiome in the metabo-
lism of drugs, such as acetaminophen, chloramphenicol, 
digoxin, and sulfasalazine [14].
While a number of studies investigated the role of the 
gut microbiota in non-alcoholic fatty liver disease [15], 
alcoholic liver disease [16], liver cirrhosis [17] and hepa-
tocellular carcinoma [18], much less attention was given 
to the mutual interactions between viral hepatitis, its 
complications, and the human microbiome. A handful 
studies considered HCV complications and their relation 
to the integrity of gut bacteria as well the immune sys-
tem [e.g. 19, 20]; however, to the best of our knowledge, 
no study has investigated the gut microbiome composi-
tion of chronic HCV patients, and whether it differs from 
healthy individuals [6]. Accordingly, we launched this 
study to explore the composition of the gut microbiomes 
of HCV patients at Beni-Suef Emergency Hospital, (Beni-




Informed consent was obtained from all subjects before 
collection of stool samples. All procedures were approved 
by the ethics committee of Faculty of Pharmacy, Cairo 
University.
Study design and subjects
This study is a prospective case–control study. Samples 
were taken from seven HCV patients and eight healthy 
individuals. All patients and healthy volunteers were 
adult males, aging between 21 and 65. Exclusion criteria 
included: inflammatory bowel syndrome, colorectal can-
cers or any systemic antibiotic use during or 3  months 
prior to the study period initiation. Essential liver func-
tions about the patients were collected. Other necessary 
information about other heart, chest, or kidney diseases, 
hypertension, and other major types of hepatitis were 
provided (Table  1; Additional file  1: Table S1), and any 
patients who failed these criteria were excluded.
Sample collection and DNA extraction
Stool samples were collected in sterilized containers 
and immediately stored at −20 ℃. On the day after the 
stool samples were collected, DNA was extracted by the 
QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA), 
and the extracted DNA samples were aliquoted and 
stored at −80 ℃.
DNA quality and quantity were measured by Nan-
oDrop 2000 UV–Vis spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA). Concentrations ranged 
between 50 and 200 ng/µl. In addition, polymerase chain 
reaction (PCR) amplification of 16S rRNA gene (using 
universal primers—27F, 1492R) followed by gel electro-
phoresis was used to confirm that the samples contained 
prokaryotic DNA. Out of 15 DNA specimens, only one 
(from a HCV patient) failed QC; thus, the rest of the 
study was conducted with DNA from six patients and 
eight healthy controls.
16S rRNA amplification of V4 region and illumina 
sequencing
Sequencing was performed at the Pacific Northwest 
National Laboratory (PNNL). The hypervariable region 
V4 of the 16S rRNA gene was amplified using forward 
primer (515f ) and reverse primer (806r). Subsequently, 
12  bp unique barcode sequences were attached to each 
sample for multiplexing. PCR amplification of the V4 
region of the 16S rRNA gene was performed accord-
ing to the Earth Microbiome Project protocol (http://
www.press.igsb.anl.gov/earthmicrobiome/emp-stand-
ard-protocols/16s/), as described by Caporaso and cow-
orkers [21], except that the 12-bp barcode sequence 
was included in the forward primer. Amplicons were 
sequenced in an Illumina MiSeq using the 300 cycle 
MiSeq Reagent Kit v2 (http://www.illumina.com/) 
according to manufacturer’s instructions.
Bioinformatics analysis
The QIIME software suite (v 1.9.1) was used for sequence 
analysis and primary statistics [22]. Different QIIME 
scripts were used as follows. First, the validate_map-
ping_file.py script was used for mapping file validation, 
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join_paired_ends.py for merging paired-end read data, 
split_libraries.py for quality filtering and demultiplexing 
the samples.
Afterwards, we followed the de novo as well as the 
closed-ref operational taxonomic unit (OTU) picking 
protocols to assign OTUs to our reads. The Greengenes 
database (V 13.8) [23] was used as a reference for the 
closed protocol. Taxonomic composition (phylum, 
class, family, etc.) was assigned by the summarize_taxa_
through_plots.py script.
We calculated the alpha diversity using alpha_diversity.
py script (Chao1, Shannon, Simpson, Phylogenetic Diver-
sity, PD, and Observed OTUs metrics) and the beta diver-
sity by beta_diversity.py script. Final data analysis and 
graphs were generated by the PhyloSeq package of the 
R project [24] as well as ggplot2 and reshape2 packages. 
LEfSe [25] was used for biomarker discovery analysis.
Results
The fecal microbiomes of six HCV patients and eight 
healthy individuals (Table 1; Additional file 1: Table S1), 
from the city of Beni Suef in Egypt, were sequenced by 
high-throughput Illumina MiSeq. High-throughput 
sequencing generated 651,912 reads that passed initial 
quality filtering (median reads per sample  =  46,219; 
median read length  =  253  bp). The quality of these 
sequence data was checked by standard quality con-
trol procedures, (e.g., total number of input sequences; 
barcode not in mapping file; reads too short after qual-
ity truncation; count of N characters exceeding limit; 
Illumina quality digit; barcode errors exceeding max; 
median sequence length), and the filtered data that 
passed quality control were used for analysis (primary 
taxon assignments are provided in Additional file  2: 
Table S2).
Even though some samples had much fewer reads than 
others, rarefaction curves indicated that the sampling 
depth was sufficient for data comparison, as all samples 
reached an asymptote (Additional file 3: Figure S1).
Primary data validation
At first, we sought to validate the raw 16S sequence data 
sets. In the absence of robust published high-throughput 
data specifically representing Egyptian gut microbiome 
composition, we chose to compare our samples to well-
documented and published gut microbiome sequences, 
such as the American Gut samples (available from 
https://www.github.com/biocore/American-Gut), to 
validate the results of taxonomic assignments in our sam-
ples. Although those samples are from individuals living 
in different geographical area and consuming different 
type of diet, the data set is still a valid representative of 
human gut microbes.
The comparison of our 14 samples to the American 
Gut samples showed that the major taxa usually associ-
ated with the human colon environment (e.g., phyla Fir-
micutes and Bacteroidetes; genera Faecalibacterium, 
Ruminococcus, and Bacteroides) were shared by both data 
sets—yet in different proportions (Additional file 3: Fig-
ures S2, S3). For example, the overall Firmicutes-to-Bac-
teroides ratio in the Egyptian samples was 1.1 (vs. 1.4 in 
the American Gut samples).
Alpha-diversity analysis
Using different diversity indices (e.g., Chao, Shannon, or 
Simpson), we found that, regardless of the used metric, 
the richness and diversity of healthy individuals’ micro-
biota were higher than those of HCV patients (Fig.  1; 
Additional file 3: Figure S4). This finding agrees with sev-
eral other human microbiome studies in which chronic 
inflammation tends to decrease biodiversity at different 
microbiome sites [26–28].
Distinct core microbiomes differentiate healthy controls 
from HCV patients
Core bacterial taxa shared by each group (healthy con-
trols and HCV patients) were identified. Overall, 22 
distinct OTUs were conserved among all samples, 
constituting a core gut microbiome. This core set is 
Fig. 1 Alpha diversity estimation in patients vs. control group (Chao 
and Shannon indexes)
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characterized by genera Streptococcus, Ruminococcus, 
Clostridium, Faecalibacterium, Bacteroides, Blautia, 
and Lachnospira in addition to some undefined mem-
bers of families Enterobacteriaceae and Clostridiaceae. 
Most of these genera were differentially distributed 
among healthy and HCV patients (Fig. 2a). Overall, 22 
OTUs were shared by both groups, 23 distinguished 
healthy controls, and 31 distinguished HCV patients 
(Fig. 2b).
Major taxonomic differences between microbiomes 
of healthy individuals and HCV patients
The ultimate goal of this study was identifying consist-
ent differences in microbial composition between the two 
analyzed groups (healthy controls and HCV patients).
On the phylum level, a mild but significant increase 
was observed in the ratios of Bacteroidetes among HCV 
patients (Kruskal–Wallis p = 0.039), whereas Firmicutes 
were slightly more abundant in healthy controls (Fig. 3a; 
Fig. 2 Core microbiomes of analyzed samples. a Main taxa of the core microbiome of all fecal samples and their relative distribution in healthy 
controls (blue) compared to patients with HCV (orange). Left panel average relative abundance of 16S sequence reads representing core taxa (in 
percent). Right panel actual values of the average proportions of 16S sequence reads representing core taxa per group. b Venn diagram represent‑
ing the core OTUs (genus level) in each analyzed group and their intersection
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Additional file  3: Figure S5); yet that observed over-
abundance of Firmicutes is not statistically significant 
(Kruskal–Wallis p = 0.301).
Genus-level analysis, however, was more informa-
tive (Fig.  3b, c; Table  2). It revealed that genus Prevo-
tella was clearly enriched in HCV patients (p = 0.038), 
possibly inflating the total Bacteroidetes abundance 
observed on the phylum level. Other minor gen-
era that were also significantly overabundant in 
HCV patients are Acinetobacter, Veillonella, and 
Phascolarctobacterium (Table  2). In addition, Faecali-
bacterium was another genus with higher abundance 
in HCV patients than in healthy controls; yet, Faecali-
bacterium abundance was less consistent among HCV 
patients. On the other hand, genera Ruminococcus and 
Clostridium were more abundant in healthy controls 
(Fig.  3b, c; Additional file  3: Figure S6). Interestingly, 
two of the healthy controls had relatively high abun-
dance of the probiotic genus, Bifidobacterium, which 
was undetected in any of the HCV patients.
Fig. 3 Boxplots representing the average proportion of each 16S sequence read attributed to each taxon between the two groups (Blue healthy 
control samples; Red patient samples). a On the phylum level, b on the genus level—major taxa; c on the genus level—minor taxa; d on the species 
level—selected taxa
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Some other sample-specific peculiarities are worth 
mentioning. For example, one patient had a fair amount 
of phylum Fusobacteria, which has been described as 
a biomarker of colon cancer [29]. Another individual 
exhibited an unusual overabundance of phylum Actino-
bacteria (Additional file 3: Figure S5).
In sum, although only one single phylum was statisti-
cally significantly different between patients and controls, 
and although only three genera were clearly differential, 
the OTU differences were sufficient to separate most 
cases into two distinct clusters, as revealed by principal 
coordinate analysis (Fig. 4). All patients, except P1, clus-
tered together, while all healthy controls but H7 clustered 
together.
The clustering was mostly affected by the relative abun-
dance of Prevotella, since patient 1 (P1) coincidentally 
had no detectable Prevotella OTUs while healthy control 
7 (H7) had an unusually higher proportion than the rest 
of the healthy control group.
However, this patient (P1)—in particular—had the 
highest proportion of Faecalibacterium, possibly suggest-
ing that the combined proportion of Prevotella and Fae-
calibacterium may be a good biomarker/predictor of the 
HCV-associated microbiome.
To run a full, unbiased investigation of which OTUs 
can serve as biomarkers, we used the LEfSe classifica-
tion tool. This analysis was able to pick some of the 
minor OTUs, which were not as obvious in the taxon 
chart analyses (Fig.  3; Additional file  3: Figures S5, S6), 
and defined a list of taxa as potential biomarkers for the 
healthy vs. HCV groups. For example, the bacteroidetes 
can serve as biomarkers for HCV patients on the phylum, 
order, and class level while a few taxa were markers of the 
healthy microbiome, most prominent of which are gen-
era Bifidobacterium, Ruminococcus and phylum Teneri-
cutes (Fig. 5).
Discussion
Over the past few years, the advancement of high-
throughput sequencing technologies led to astonishing 
discoveries about the microbial communities that live 
in and on the human body, the human microbiota. The 
human gut contains trillions of microbial cells, many of 
which are metabolically active. As 70 % of the liver blood 
Table 2 Genera that are statistically significantly different 






Higher in HCV patients
 Acinetobacter 0 0.0001 N/A 0.003
 Prevotella 0.1501 0.3555 0.42 0.038
 Veillonella 0.0006 0.0107 0.06 0.056
 Phascolarctobacte-
rium
0.0012 0.0158 0.08 0.057
Higher in healthy controls
 Ruminococcus 0.0064 0.0027 2.37 0.006
 Parabacteroides 0.0190 0.0007 27.14 0.021
 Butyricimonas 0.0021 0.0002 10.5 0.056
Fig. 4 Principal coordinate analysis representing the beta diversity estimated by the weighted UNIFRAC method [30]. Each sphere represents one 
sample (Blue healthy control, H1–H8; Red patients with HCV, P1–P8). The three principal coordinates (PC1 through PC3) explain 55.68, 10.28 and 
9.72 %, respectively
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Fig. 5 LEfSe classification analysis
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access is derived from the gastrointestinal tract (GIT) 
through the portal vein, it is expected that compositional 
changes in the gut microbial community will affect the 
liver physiological state (gut-liver axis). On the other 
hand, the liver has major impact on digestion and, thus, 
the liver health and status will directly impact the intesti-
nal environment and its resident microbes.
Surprisingly, little is known about the gut microbi-
ome of HCV patients [6, 7], although the disease has 
>2 % global prevalence. Given the chronic nature of the 
disease, and its unusually high prevalence in Egypt, we 
sought to explore the gut microbiome of HCV patients 
with no other underlying disease, in comparison with 
healthy controls from the same geographical area (having 
similar diet and lifestyle). To this end, we sequenced and 
analyzed the microbial community structure in six HCV 
patients and eight healthy controls, and we observed a 
few consistent differences. Genera Prevotella and Faecal-
ibacterium were more enriched in HCV patients in addi-
tion to the minor genera Acinetobacter, Veillonella, and 
Phascolarctobacterium, while Ruminococcus, Bifidobac-
terium, and some clostridia were more abundant among 
healthy controls.
In agreement with several other microbiome studies, a 
higher microbial diversity was observed in fecal commu-
nities of healthy controls than in the patient group. These 
patients were not in-patients and thus were not in a pro-
tected environment or under limited dietary options to 
suggest that this decrease in diversity is a consequence of 
hospitalization. More likely, the lower diversity is a result 
of complex factors: one major factor, disruption of home-
ostasis caused by the chronic HCV infection, may have 
induced a state of dysbiosis in the intestine. Additionally, 
the immune system’s adaptation to the state of chronic 
infection may be another major factor in decreasing 
gut microbial diversity. Cytokines, IgA levels, and T cell 
mobilization are all possible factors that control that 
diversity.
An interesting characteristic of HCV is that the virus 
invades gastric cells as both of the liver and gastric cells 
share common embryogenic origin. Moreover, HCV 
infects the gastric B-lymphocytes, which produce IgA 
antibodies [31]. IgA is known to modulate the gut micro-
biome composition and abundance [32], possibly behind 
the higher than average ratios of Prevotella and Para-
prevotella in the HCV patients’ samples (Fig. 6).
Perhaps the most significant influence of HCV on 
the gut microbiome is related to the pathophysiologi-
cal alterations of the liver, eventually interfering with its 
digestive functions. For example, HCV infection leads 
to low bile production, subsequently leading to bacte-
rial overgrowth and changes in gut microenvironment 
and microbial community [33–38]. Another interesting 
finding, previously reported as a link between the gut and 
the liver in cirrhotic patients, is bacterial translocation. 
Bacterial translocation is the migration of gut bacteria or 
their products to mesenteric lymph nodes or possibly to 
other organs, including the liver [28, 39]. Causes of bacte-
rial translocation include immune dysfunction, alteration 
of the luminal factors and altered intestinal permeabil-
ity. A direct link between viral hepatitis and bacterial 
translocation has not been established, but studies sug-
gested that the degree of liver disease in patients with 
HCV might be associated with microbial translocation 
[19], and bacterial translocation was indeed observed in 
chronic HCV patients [20]. Thus, it is not unlikely that 
liver damage and subsequent alterations in homeostasis 
as well as reduction in biliary secretion may be causing 
bacterial translocation, as we suggest in our hypothesized 
model (Fig. 6). Future studies should address this link in 
more depth.
One more possible reason behind the alteration in 
microbial composition, particularly the overabundance 
of Prevotella in HCV patients, is the dietary carbohydrate 
intake. In healthy individuals, high carbohydrate intake 
has been associated with expansion of Prevotella [40]. In 
HCV patients, it is possible that impairment of digestion 
and absorption may lead to higher carbohydrates con-
centrations in small and large intestine, and consequently 
expansion of Prevotella.
Last but not least, Prevotella copri abundance has been 
correlated with Th17 and IL-17 (inflammatory mediator), 
which are reportedly at high levels in HCV patients [41, 
42]. In support of our hypothesized model (Fig. 6), a very 
recent study used a novel probiotic mixture to slow down 
HCC growth in mice through suppression of Th17 cells 
and IL-17 [43].
HCV patients in this study have higher abundance of 
Faecalibacterium prausnitzii in their fecal microbiomes 
(Fig. 3d), which has been described to have anti-inflam-
matory effects [44]. It is not clear which mechanism 
drives the expansion of F. prausnitzii in some patients but 
not in others; however, most likely it is related to the rela-
tive cytokine levels in the intestinal environment.
Conclusions
In conclusion, we analyzed the fecal microbiomes of six 
patients with stage 4 HCV infection in comparison to 
eight healthy individuals from the same city and validated 
the data by comparing them to a larger data set ran-
domly selected from the American Gut samples. Patients 
with HCV had a few significant changes that may be 
related to liver-controlled homeostasis, protein synthe-
sis, lipid digestion, or possibly to bacterial translocation, 
immune modulation, or a combination of all of the above 
mechanisms.
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Based on our findings and on literature, we suggest a 
brief model (Fig.  6) that could explain the changes we 
observed in microbiota composition. This model can 
serve as a working hypothesis for future studies with 
larger number of samples from more individuals, and/or 
deeper analysis of metagenomic sequence reads. The role 
of Prevotella/Faecalibacterium vs. Ruminococcus/Bifido
bacterium relative abundance as biomarkers for chronic 
HCV infections, or disease progression, is worth further 
investigations.
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